BBlogFlow

PAHO and Curaçao sign first Country Cooperation Strategy to strengthen health system resilience and primary health care - Pan American Health Organization (PAHO)

·Oct 1, 2026
Source: Pan American Health Organization (PAHO)
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

The six-year strategy will support stronger primary health care, disease prevention and more resilient and sustainable health systems. Washington, D. C., 1 October 2026 (PAHO) – The Pan American Health Organization/World Health Organization (PAHO/WHO) and the Government of Curaçao today signed the first Country Cooperation Strategy (CCS) for Curaçao, covering 2026–2031, to support national health priorities and strengthen the country’s health system. The agreement was signed on the margins of the 63rd PAHO Directing Council, taking place this week in Washington, D. C. The agreement aligns with Curaçao’s National Health Strategy, Un Korsou Salú (A Healthy Curaçao), and PAHO’s Strategic Plan 2026–2031. It establishes three priorities: strengthening integrated, people-centered and climate-resilient primary health care; improving the prevention and management of communicable diseases, noncommunicable diseases and mental health conditions; and building more resilient, sustainable and efficient health systems.

This article is an excerpt. To read the full content, visit the original source. Pan American Health Organization (PAHO)

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·